S100 calcium-binding protein B in older patients with depression treated with electroconvulsive therapy

Carlier, Angela; Boers, Kimberly; Veerhuis, Robert; Bouckaert, Filip; Sienaert, Pascal; Eikelenboom, Piet; Vandenbulcke, Mathieu; Stek, Max L.; Exel, Eric van; Dols, Annemiek; Rhebergen, Didi

doi:10.1016/j.psyneuen.2019.104414

Cited by 6 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis of the 3 first studies that included 51 responders and 73 non-responders found that S100B levels at baseline were significantly elevated in responders ( Shi et al, 2020 ). These findings were similar in patients treated with electroconvulsive therapy, where higher baseline S100B levels were associated with better clinical outcome at both 5 and 30 posttreatment days ( Arts et al, 2006 ) and long-term remission time ( Carlier et al, 2010 ; Maier et al, 2018 ), although no relationship with treatment response was reported ( Kranaster et al, 2014 ). Our findings reinforce these previous data and might suggest that patients with high baseline S100B have an increase in this neurotrophic factor, which may promote the antidepressant response ( Ambrée et al, 2016 ).…”

Section: Discussionsupporting

confidence: 52%

High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers

Navinés

Oriolo

Horrillo

et al. 2022

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

Background The relationship between antidepressant response and glial, inflammatory, and metabolic markers is poorly understood in depression. This study assessed the ability of biological markers to predict antidepressant response in major depressive disorder (MDD). Methods We included 31 MDD outpatients treated with escitalopram or sertraline for 8 consecutive weeks. The Montgomery-Asberg Depression Rating Scale (MADRS) was administered at baseline and at week 4 and 8 of treatment. Concomitantly, blood samples were collected for the determination of serum S100B, CRP, and HDL-C levels. Treatment response was defined as ≥50% improvement in the MADRS score from baseline to either week 4 or 8. Variables associated with treatment response were included in a linear regression model as predictors of treatment response. Results Twenty-seven patients (87%) completed 8 weeks of treatment; 74% and 63% were responders at week 4 and 8, respectively. High S100B and low HDL-C levels at baseline were associated with better treatment response at both time-points. Low CRP levels were correlated with better response at week 4. Multivariate analysis showed that high baseline S100B levels and low baseline HDL-C levels were good predictors of treatment response at week 4 (R 2=0.457, p=0.001), while S100B was at week 8 (R 2=0.239, p=0.011). Importantly, baseline S100B and HDL-C levels were not associated with depression severity and did not change over time with clinical improvement. Conclusions Serum S100B levels appear to be a useful biomarker of antidepressant response in MDD even when considering inflammatory and metabolic markers.

show abstract

Section: Discussionsupporting

confidence: 52%

High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers

Navinés

Oriolo

Horrillo

et al. 2022

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…Patients with intermediate S100B levels were more likely to achieve a remission of symptoms after ECT than patients with lower S100B levels. There also was no difference in S100B between baseline and post-ECT in both: remitters and non-remitters [ 85 ]. Palmio et al (2010) found that a reduction in depressive symptoms after ECT treatment correlated with high S100B levels at 2 and 6 h post-ECT [ 86 ].…”

Section: Resultsmentioning

confidence: 99%

“…S100B levels were also studied in the context of cognitive functions [ 10 , 17 , 28 , 45 , 54 , 115 ], event-related potentials [ 64 , 69 , 90 ], neuroimaging [ 11 , 52 , 70 , 72 , 97 , 98 ], and electroconvulsive therapy [ 83 , 85 , 86 , 87 , 88 , 89 ]. Finally, suicidal behavior, regardless of diagnosis status, was investigated concerning its correlation with S100B levels, also with inconsistent results, where no relationships [ 118 ], positive correlation with severity of suicidal ideations [ 119 ], or negative correlation with the number of suicidal attempts [ 43 ] were found.…”

Section: Discussionmentioning

confidence: 99%

Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review

Kozlowski,

Bargiel,

Grabarczyk

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Five major psychiatric disorders: schizophrenia, major depressive disorder, bipolar disorder, autistic spectrum disorder, and attention-deficit/hyperactivity disorder, show a shared genetic background and probably share common pathobiological mechanisms. S100B is a calcium-binding protein widely studied in psychiatric disorders as a potential biomarker. Our systematic review aimed to compare studies on peripheral S100B levels in five major psychiatric disorders with shared genetic backgrounds to reveal whether S100B alterations are disease-specific. EMBASE, Web of Science, and PubMed databases were searched for relevant studies published until the end of July 2023. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA) guidelines. Overall, 1215 publications were identified, of which 111 full-text articles were included in the systematic review. Study designs are very heterogeneous, performed mostly on small groups of participants at different stages of the disease (first-episode or chronic, drug-free or medicated, in the exacerbation of symptoms or in remission), and various clinical variables are analyzed. Published results are inconsistent; most reported elevated S100B levels across disorders included in the review. Alterations in S100B peripheral levels do not seem to be disease-specific.

show abstract

“…The expression of S100B and RAGE can be reduced by stress and depression, and these effects can be reversed or prevented by antidepressant treatment [ 7 ]. In several brain regions, including the hippocampus, a decrease in the number of S100B-positive cells and a decrease in glial fibrillary acidic protein (GFAP) expression indicate a significant reduction in glial cell density [ 25 ]. Animal studies have shown reduced S100B levels in cerebrospinal fluid (CSF), the hippocampus [ 26 ], and the prefrontal cortex [ 27 ] of rats after chronic, unpredictable stress and in the hippocampus of pregnant rats after exposure to stress [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Gender differences in plasma S100B levels of patients with major depressive disorder

Wu,

Lu,

Kong

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

Background Low concentrations of S100B have neurotrophic effects and can promote nerve growth and repair, which plays an essential role in the pathophysiological and histopathological alterations of major depressive disorder (MDD) during disease development. Studies have shown that plasma S100B levels are altered in patients with MDD. In this study, we investigated whether the plasma S100B levels in MDD differ between genders. Methods We studied 235 healthy controls (HCs) (90 males and 145 females) and 185 MDD patients (65 males and 120 females). Plasma S100B levels were detected via multifactor assay. The Mahalanobis distance method was used to detect the outliers of plasma S100B levels in the HC and MDD groups. The Kolmogorov–Smirnov test was used to test the normality of six groups of S100B samples. The Mann–Whitney test and Scheirer-Ray-Hare test were used for the comparison of S100B between diagnoses and genders, and the presence of a relationship between plasma S100B levels and demographic details or clinical traits was assessed using Spearman correlation analysis. Results All individuals in the HC group had plasma S100B levels that were significantly greater than those in the MDD group. In the MDD group, males presented significantly higher plasma S100B levels than females. In the male group, the plasma S100B levels in the HC group were significantly higher than those in the MDD group, while in the female group, no significant difference was found between the HC and MDD groups. In the male MDD subgroup, there was a positive correlation between plasma S100B levels and years of education. In the female MDD subgroup, there were negative correlations between plasma S100B levels and age and suicidal ideation. Conclusions In summary, plasma S100B levels vary with gender and are decreased in MDD patients, which may be related to pathological alterations in glial cells.

show abstract

S100 calcium-binding protein B in older patients with depression treated with electroconvulsive therapy

Cited by 6 publications

References 49 publications

High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers

High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers

Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review

Gender differences in plasma S100B levels of patients with major depressive disorder

Contact Info

Product

Resources

About